openPR Logo
Press release

Global Bispecific Antibody Market To Surpass USD 10 Billion By 2026

02-03-2020 09:30 AM CET | Health & Medicine

Press release from: Kuick Resarch

"Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlight:
o Global Bispecific Antibody Market Opportunity: > US$ 10 Billion
o Global Bispecific Antibody Market Growth: 118% CAGR (2015 -2019)
o Global Bispecific Antibody Market Growth In 2019: 280% (> US$ 1.5 Billion)
o Global Bispecific Antibody Pipeline: 333 Drug
o Commercially Available Bispecific Antibodies: 2 (Blincyto & Hemlibra)
o Hemlibra Sales & Market Share 2019: > US$ 1.4 Billion & > 80%

Download Report: https://www.kuickresearch.com/report-global-bispecific-antibody-market-opportunity,-drug-sales--and-clinical-trials-insight-2026.php

1. Introduction to Bispecific Monoclonal Antibody

1.1 Overview of Monoclonal Antibody
1.2 Overview of Bispecific Monoclonal Antibody
1.3 Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

2. The Engineering & Development of Bispecific Antibodies

2.1 Bispecific Antibodies Similar to IgG

2.1.1 Quadroma (Hybrid Hydromas) Approach
2.1.2 "Knobs Into Holes" Approach
2.1.3 CrossMab Approach
2.1.4 Dual-Variable-Domain Immunoglobulin Approach

2.2 Small Bispecific Antibodies

2.2.1 Bispecific Diabodies
2.2.2 Bispecific T-Cell Engager Antibodies (BiTEs)

3. Mechanism Of Action Of Bispecific Antibody

3.1 Trifunctional Antibody: Catumaxomab (Removab)
3.2 Blinatumomab

4. Applications of Bispecific Antibodies in Diagnostic & Treatment

4.1 BsMAb for Diagnosis of Bacterial & Viral Infectious Diseases
4.2 BsMAb for Cancer Diagnostic
4.3 BsAbs Blocking Signaling Pathways
4.4 BsAbs Targeting Tumor Angiogenesis
4.5 Specific Delivery of Effector Compounds to Targets
4.6 Bispecific Antibodies & Gene Therapy

5. Global Bispecific Antibody Market Outlook

5.1 Current Market Scenario

5.2 Availability of Bispecific Antibodies
5.2.1 Catumaxomab (Removab)
5.2.2 Blinatumomab
5.2.3 Emicizumab
5.2.4 Duligotumab
5.2.5 SAR 156597

6. Approved Bispecific Antibody Dosage & Price Analysis

6.1 Blincyto
6.2 Hemlibra

7. Approved Bispecific Antibody Sales Analysis

7.1 Blincyto
7.2 Hemlibra

8. Global Bispecific Antibodies Clinical Pipeline Overview

8.1 By Phase
8.2 By Country/Region
8.3 By Company
8.4 By Indication
8.5 Orphan Designated Bispecific Antibodies

9. Global Bispecific Antibodies Clinical Pipeline By Company, Indication & Phase

9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III

10. Marketed Bispecific Antibodies Clinical Insight

10.1 Blinatumomab - Amgen
10.2 Emicizumab - Chugai Pharmaceutical

11. Global Bispecific Antibody Market Dynamics

11.1 Favorable Market Parameters
11.2 Commercialization Challenges

12. Global Bispecific Antibody Market Future Prospects

13. Competitive Landscape

13.1 Ablynx
13.2 Adimab
13.3 Affimed Therapeutics
13.4 Amgen
13.5 AstraZeneca (MedImmune)
13.6 Chugai Pharmaceutical
13.7 Eli Lilly
13.8 EMD Serono
13.9 Emergent BioSolutions
13.10 Genentech
13.11 Genmab
13.12 Immunomedics
13.13 Jounce Therapeutics
13.14 MacroGenics
13.15 Merus
13.16 Neovii Biotech
13.17 NovImmune SA
13.18 OncoMed Pharmaceuticals
13.19 Pieris
13.20 Regeneron Pharmaceuticals
13.21 Roche
13.22 Sanofi

List of Figures

Figure 1-1: Advantages of Bispecific Antibodies

Figure 2-1: Types of Approaches to Form IgG like Bispecific Antibodies
Figure 2-2: Method of Formation of Hybrid Hybridoma
Figure 2-3: Limitations of Hybrid Hybridoma
Figure 2-4: Steps involved in "Knobs into Holes" Approach
Figure 2-5: Three different CrossMabs are Obtained by Three Different Modifications
Figure 2-6: Method for formation of Dual-Variable-Domain Immunoglobulin
Figure 2-7: Advantages of Dual Variable Domain Immunoglobulin approach
Figure 2-8: Types of Bispecific Antibodies

Figure 3-1: Mechanism of Action of Bispecific Monoclonal Antibody
Figure 3-2: Mechanism of Action of Catumaxomab
Figure 3-3: Mechanism of Action of Blinatumomab

Figure 4-1: Applications of Bispecific Antibodies

Figure 5-1: Global - Bispecific Antibody Market Size (US$ Million), 2015 - 2019
Figure 5-2: US v/s ROW - Bispecific Antibody Market Share (%) , 2018
Figure 5-3: US v/s ROW - Bispecific Antibody Market Share (%) , 2019
Figure 5-4: Global - Bispecific Antibody Market Size (US$ Million) by Products (Blincyto & Hemlibra) , 2018 & 2019
Figure 5-5: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra) , 2018
Figure 5-6: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra) , 2019
Figure 5-7: Global - Bispecific Antibody Quarterly Sales (US$ Million), by Products (Blincyto & Hemlibra), 2019
Figure 6-1: Blincyto - Recommended Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, December'2019
Figure 6-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days) , December'2019
Figure 6-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-Cell Precursor ALL (US$), December'2019
Figure 6-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, December'2019
Figure 6-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), December'2019
Figure 6-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), December'2019
Figure 6-7: Blincyto - Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), December'2019
Figure 6-8: Hemlibra - Cost for Single Unit of 30mcg & 150mcg Subcutaneous Injection (US$), December'2019
Figure 6-9: Hemlibra - Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/Kg/Week), December'2019
Figure 6-10: Hemlibra - Average Monthly & Annual Cost for Treatment of Hemophilia A (US$), December'2019

Figure 7-1: Blincyto - Sales Value (US$ Million), 2015 - 2019
Figure 7-2: US - Blincyto Sales Value (US$ Million), 2016 - 2019
Figure 7-3: Global ( Ex USA) - Blincyto Sales Value (US$ Million), 2016 - 2019
Figure 7-4: Blincyto - Quarterly Sales Value (US$ Million), 2018
Figure 7-5: Blincyto - Quarterly Sales Value (US$ Million), 2019
Figure 7-6: Blincyto - US v/s Rest of World Share in Sales Value (%), 2018
Figure 7-7: Blincyto - US v/s Rest of World Share in Sales Value (%), 2019
Figure 7-8: Hemlibra - Sales Value by Countries (US$ Million), 2019
Figure 7-9: Hemlibra - Sales Value by Countries (US$ Million), 2018
Figure 7-10: Hemlibra - Sales Value Share by Countries (%), 2018
Figure 7-11: Global - Hemlibra Quarterly Sales Value (US$ Million), 2018
Figure 7-12: Global - Hemlibra Half Yearly Sales Value (US$ Million), 2018 & 2019
Figure 7-13: Hemlibra - Half Year Sales Value by Countries (US$ Million), 2018 & 2019
Figure 7-14: Hemlibra - Quarterly Sales Value (US$ Million), 2019
Figure 7-15: Hemlibra - 9 Months Sales Value by Countries (US$ Million), 2019
Figure 7-16: Hemlibra - 9 Month Sales Value Share by countries (%), 2019

Figure 8-1: Global - Bispecific Antibodies Clinical Pipeline by Phase (%), 2020 till 2026
Figure 8-2: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2020 till 2026
Figure 8-3: Global - Bispecific Antibodies in Clinical Pipeline by Country (Numbers), 2020 till 2026
Figure 8-4: Global - Bispecific Antibodies in Clinical Pipeline by Company (Numbers), 2020 till 2026
Figure 8-5: Global - Bispecific Antibodies in Clinical Pipeline by Indication (Numbers), 2020 till 2026
Figure 8-6: Global - Bispecific Antibodies in Clinical Pipeline by Orphan Status (Numbers), 2020 till 2026

Figure 11-1: Favorable Market Parameters Global Bispecific Antibody Market
Figure 11-2: Commercialization Challenges for Bispecific Antibody

Figure 12-1: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2020 - 2026

Figure 13-1: Ablynx - Clinical Pipeline
Figure 13-2: Affimed Therapeutics - Clinical Pipeline
Figure 13-3: Amgen - Clinical Pipeline
Figure 13-4: EMD Serono - Clinical Pipeline
Figure 13-5: Emergent Bioscience - Clinical Pipeline
Figure 13-6: Genmab - Clinical Pipeline
Figure 13-7: Jounce Therapeutics - Clinical Pipeline
Figure 13-8: MacroGenics - Clinical Pipeline
Figure 13-9: Merus - Clinical Pipeline
Figure 13-10: Novimmune - Clinical Pipeline
Figure 13-11: OncoMed - Clinical Pipeline
Figure 13-12: Pieris Pharmaceuticals - Clinical Pipeline
Figure 13-13: Roche - Clinical Pipeline


List of Tables

Table 2-1: List of Bispecific Antibodies Formed by Hybrid Hybridoma Method
Table 2-2: List of Bispecific Antibodies Formed by DART
Table 2-3: List of Bispecific Antibodies Formed by BiTE Method
Table 2-4: List of Other BiTEs
Table 4-1: Bispecific Antibodies Targeting Cancer

Contact:
Neeraj Chawla
neeraj@kuickresearch.com
+91-11-47067990

Delhi,India, Tel; +91-11-47067990

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Bispecific Antibody Market To Surpass USD 10 Billion By 2026 here

News-ID: 1916319 • Views: 530

More Releases from Kuick Resarch

Global Antibody Drug Conjugate Market Sales Size Opportunity To Surpass US$ 10 B …
"Novel Cancer Antibody Drug Conjugates to Drive Cancer Therapeutics Market With More Than 290 Cancer Antibodies In Clinical Trials Pipeline Says Kuick Research" "Global Cancer Antibody Drug Conjugate Market, Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Cancer Antibody Drug Conjugate (ADC) Pipeline: 297 Drugs • Marketed Cancer Antibody Drug Conjugate: 9 Drugs • Antibody Drug Conjugate Marketed Opportunity: > US$ 13 Billion By 2026 • Majority of Drug Trials Are For Second Line Therapy
Global Cell Therapy Market Stem Cell Therapy Market Size Sales Growth Clinical T …
Global Cell Therapy Market Size Sales Opportunity To Surpass USD 40 Billion By 2027 Says Kuick Research Report Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027 "Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market: > USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Cell Therapy Price & Product Insight By Region/Country • Clinical
Global Small Molecule Targeted Cancer Drug Market Size Sales To Reach US$ 130 Bi …
"Global Small Molecule Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" Report Highlights: • Global Small Molecule Cancer Drug Market: > US$ 125 Billion by 2026 • USA Dominates Global Small Molecule Cancer Drug Market: >50% Share • Number of Small Molecule Cancer Drugs In Clinical Trials: >2500 Drugs • Small Molecule Cancer Drugs Dosage, Sales, Price & Patent Insight: 175 Drugs • Small Molecule Drug Insight by Cancer • Clinical Trials Insight
GCC Clinical Trial Market Outlook Insight 2025
"GCC Clinical Trial Market Outlook 2025" Report Highlights: • GCC Clinical Trial Market Opportunity: >US$ 500 Million • GCC Disease Prevalence & Statistics • Saudi Arabia Dominating GCC Clinical Trial Landscape: > 500 Trials • Clinical Trials for Cancer in GCC: > 120 Trials • Guidelines For Conducting Clinical Trials by Country • Ongoing Clinical Trials Insight by Country Download Report: https://www.kuickresearch.com/report-report-report-report-report-report-report-report-gcc-clinical-trial-market-size-number--data-regulation-registration Table of Contents 1. GCC Clinical Market Regional Insights 2. GCC Clinical Trial Market Dynamics 2.1 Driving Forces for GCC Clinical Trial

All 5 Releases


More Releases for Figure

THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER!
FOR IMMEDIATE RELEASE THE WORLD'S MOST CONTROVERSIAL ACTION FIGURE...EVER! Contact: William Hirsch - Schlock Toys @ +1-949-677-9353 or DocSchlock@SchlockToys.com Featured on Tomi with Fox News host Tomi Lahren! SCHLOCK TOYS join forces with Kickstarter to Make Toys Great Again! The Kickstarter campaign page can be found HERE: https://www.kickstarter.com/projects/schlocktoys/collectors-edition-talking-trump-2020-man-of-action-figure/description “What a great message to be sent, and I think Trump himself would love this and that he’d be excited about it!” - Tomi Lahren, Fox News “You
Global Leisure Boats Market Dynamic, Value, Figure, Forecast 2018-2025
Qyresearchreports include new market research report Global Leisure Boats Market Professional Survey Report 2018 to its huge collection of research reports. This report studies Leisure Boats in Global market,especially in North America,China,Europe,Southeast Asia,Japan and India,with production,revenue,consumption,import and export in these regions,from 2013 to 2018,and forecast to 2025. This report focuses on top manufacturers in global market,with production,price,revenue and market share for each manufacturer,covering Riva Sunseeker Ferretti Lurssen Azimut Wally Princess Pershing Free Sample of this report is available upon request @
Global Protective Packaging Market Dynamic, Value, Figure, Forecast 2018-2025
Qyresearchreports include new market research report Global Protective Packaging Market Professional Survey Report 2018 to its huge collection of research reports. This report studies Protective Packaging in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and
Lawn Mower Market Dynamic, Value, Figure, Forecast 2018-2025
Qyresearchreports include new market research report 2018-2025 Lawn Mower Report on Global and United States Market, Status and Forecast, by Players, Types and Applications to its huge collection of research reports. This report studies the Lawn Mower market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top players in global and United States market, and splits the
Glissandra Skincare Proudly Supports World Figure Skating Champion, Patrick Chan
Glissandra Skincare is honoured to have participated in the World Chinese Business Association of Canada’s 2012 Fundraising Dinner to support Patrick Chan. Vancouver, BC, Canada, February 21, 2012 -- On Saturday, February 18, 2012, hundreds of guests packed the Victoria Chinese Restaurant in Downtown Vancouver to celebrate Canadian figure skater, Patrick Chan. The event was hosted by the World Chinese Business Association of Canada and raised almost $60,000 to assist in
Personal injury solicitors help client to reach five-figure settlement
Fentons Solicitors LLP, one of the UK's leading personal injury solicitors, has achieved a five-figure settlement victory for a client that suffered multiple severe injuries when the car he was a passenger in struck a line of parked cars. The 48-year old former hod-carrier was a front seat passenger when the driver lost control of the car and collided with a number of stationary vehicles. Fentons helped him to reach an